about
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brainThe Contribution of GMP-grade Hospital Preparation to Translational ResearchIdentification and functional characterization of a novel human and rat riboflavin transporter, RFT1Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial.Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data.A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment.Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 CellsImpaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndromeDisruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice.Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52.Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery.Extracellular nucleotides from dying cells act as molecular signals to promote wound repair in renal tubular injury.Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins.Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells.Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients.Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1.A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head.Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach.Taxanes and platinum derivatives impair Schwann cells via distinct mechanismsSafety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.A novel protocol for antibiotic prophylaxis based on preoperative kidney function in patients undergoing open heart surgery under cardiopulmonary bypass.Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in JapanesRisk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience.MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients.Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation.Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption.Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B.Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis.Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury.Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts
P50
Q24312070-E539302A-312F-4B4B-BCF6-C14C5B0DC4A1Q28082557-86378170-D92D-4119-AEBB-CA986B3AE548Q28564642-A35BC318-04E7-4E09-A6AE-64C58664ED5BQ30444380-DB15200A-67F7-4A0B-A28F-E0216D6E8375Q30478217-5B5D4D49-E7E3-483F-A507-107D9ECF3A01Q31049063-E1F90241-5113-4325-AA88-75566DD1B136Q31165099-22F2A581-8644-46DE-893C-2D7A23DEE739Q34537290-255F2B25-CD85-417D-9A43-601E067B5120Q34542782-1F009B75-F376-4496-A370-4F3B44FF93F3Q35750388-DD67505E-EC80-42D7-B6A8-C31C88B9AECEQ36315260-1F947B35-154D-4C33-8B97-455546BA7820Q36980194-292122B3-CF48-4028-8994-34BF826F077BQ38090800-1AE474F3-15A7-4F45-84B7-C7F0C184C4EFQ38440279-8C3AD1B0-2FDE-4405-8E5B-7F262B3F6589Q38786489-215FCE2C-8E30-4CA6-9C66-7FE31A5037EBQ38944042-A95EF01F-9ED2-4F19-9020-A6BD5B416D91Q39116791-577C0589-6D58-4091-90DD-823D5729B56AQ39193143-68848BB6-FF16-420D-9914-29DDBC55EF09Q39762264-6BCA89C0-543E-44D0-AAA8-1C7B9343EBCCQ39949624-4D9B804E-5A23-4AC6-A8C9-4023E2735FDEQ39954967-CD7C9A6D-108C-476B-A885-DBC20D855F64Q40160185-3D3B0AAE-D15B-4ECA-B883-E0557FBD94E6Q40235684-9708DF08-3C2F-4556-BE29-22A24D20466EQ41075945-CAA19AE2-E477-4151-B7C1-81AC2463AF52Q41090665-20DDCEB0-C17B-480C-AE08-873AE8365030Q41272598-1DF9A613-3CD7-442C-8538-688405D30468Q41951897-43250958-E9EB-4C12-BD68-788A2612BA4EQ42247175-D3169A59-B1C5-4466-9320-B87B061B2218Q43250973-CD4DA61D-EB22-4F33-85F8-969E51A30429Q43577453-EC108759-7BBA-4C9C-AFF2-FAC4AB75DCE6Q46097641-91161976-50F0-4824-81E7-88E2232F79E6Q46097647-B18719EC-6655-4F3C-9EE1-E6E019E5F03FQ47678205-3F1EE056-C623-40F0-AD6A-CD0AFF085F55Q48231215-F41235A5-060E-4CED-A2DB-BC4CC2334DDAQ50049887-FAF0A239-E537-4E82-8448-94732905C806Q50227855-84F13143-B73B-47EE-897C-EE30089ACF98Q51532162-E6C66DF6-33E4-4D4F-BDD2-C89622C7BF83Q51729546-37648367-049B-4C7A-BA32-7ACEA796E2EFQ53547205-F991B88D-6FC1-4F84-BF24-0D8261476314Q57025852-204D02CF-264B-4298-B17A-E71C941DF8A3
P50
description
researcher, ORCID id # 0000-0002-8057-6768
@en
wetenschapper
@nl
name
Atsushi Yonezawa
@ast
Atsushi Yonezawa
@en
Atsushi Yonezawa
@es
Atsushi Yonezawa
@nl
type
label
Atsushi Yonezawa
@ast
Atsushi Yonezawa
@en
Atsushi Yonezawa
@es
Atsushi Yonezawa
@nl
prefLabel
Atsushi Yonezawa
@ast
Atsushi Yonezawa
@en
Atsushi Yonezawa
@es
Atsushi Yonezawa
@nl
P106
P1153
7006444596
P31
P496
0000-0002-8057-6768